Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$TEVA Q1 '25 Earnings Results & Recap Teva's Q1 2025 non-GAAP EPS of $0.52 exceeded the estimate of $0.46, while revenue of $3.9B slightly missed the $3.99B estimate; the company raised the low end of its 2025 revenue guidance for the drug AUSTEDO to $1.95B and expressed confidence in achieving a 30% operating margin by 2027.
1

Since Post

Full Details

Advertisement|Remove ads.